SG Americas Securities LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 53.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,088 shares of the medical instruments supplier's stock after purchasing an additional 3,168 shares during the period. SG Americas Securities LLC's holdings in Becton, Dickinson and Company were worth $2,082,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Parsons Capital Management Inc. RI boosted its position in shares of Becton, Dickinson and Company by 3.7% during the 1st quarter. Parsons Capital Management Inc. RI now owns 2,660 shares of the medical instruments supplier's stock worth $609,000 after acquiring an additional 95 shares in the last quarter. GAMMA Investing LLC increased its holdings in Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after buying an additional 748 shares in the last quarter. Cardinal Capital Management Inc. lifted its position in shares of Becton, Dickinson and Company by 5.6% during the 1st quarter. Cardinal Capital Management Inc. now owns 135,563 shares of the medical instruments supplier's stock valued at $31,052,000 after acquiring an additional 7,130 shares during the period. Yousif Capital Management LLC increased its position in shares of Becton, Dickinson and Company by 8.3% in the first quarter. Yousif Capital Management LLC now owns 64,653 shares of the medical instruments supplier's stock valued at $14,809,000 after buying an additional 4,950 shares in the last quarter. Finally, Pallas Capital Advisors LLC grew its position in shares of Becton, Dickinson and Company by 23.8% in the first quarter. Pallas Capital Advisors LLC now owns 2,223 shares of the medical instruments supplier's stock valued at $509,000 after purchasing an additional 427 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.
Becton, Dickinson and Company Stock Performance
NYSE BDX traded up $0.81 on Monday, hitting $173.02. The stock had a trading volume of 206,170 shares, compared to its average volume of 1,968,983. The company's 50-day moving average is $183.03 and its two-hundred day moving average is $212.95. The stock has a market cap of $49.59 billion, a price-to-earnings ratio of 28.74, a P/E/G ratio of 1.63 and a beta of 0.25. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same quarter in the previous year, the firm posted $3.17 EPS. The firm's quarterly revenue was up 4.5% on a year-over-year basis. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's payout ratio is 79.39%.
Analyst Upgrades and Downgrades
A number of analysts recently commented on BDX shares. Stifel Nicolaus decreased their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. William Blair downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Morgan Stanley lowered their target price on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Piper Sandler downgraded Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a research note on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and an average price target of $219.22.
Get Our Latest Report on Becton, Dickinson and Company
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. The trade was a 8.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Shan sold 1,166 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president now owns 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,104 shares of company stock valued at $399,675 in the last quarter. Insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
